$0.754000
0.00390.52%
Last update: 11:58 AM
15 minutes delayed
Comments
Loading...
Bolt Biotherapeutics
BOLTNASDAQ
Latest news for Bolt Biotherapeutics (NASDAQ:BOLT) Stock
Bolt Biotherapeutics Stock (NASDAQ: BOLT)
Categories: All
Wednesday, May 15, 2024
- Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- Leerink Partners Downgrades Bolt Biotherapeut...
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Jones Trading Downgrades Bolt Biotherapeutics...
- HC Wainwright & Co. Downgrades Bolt Biotherap...
- This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Today
- Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Bolt Biotherapeutics shares are trading lower...
- Guggenheim Downgrades Bolt Biotherapeutics to...
- Stifel Downgrades Bolt Biotherapeutics to Hol...
Tuesday, May 14, 2024
Wednesday, April 03, 2024
Friday, March 22, 2024
Thursday, March 21, 2024
Tuesday, December 05, 2023
Tuesday, November 21, 2023
Thursday, November 09, 2023
Monday, October 23, 2023
Tuesday, October 17, 2023
Monday, October 16, 2023
Monday, October 02, 2023
Friday, September 29, 2023
Thursday, September 28, 2023
Tuesday, September 12, 2023
Tuesday, August 22, 2023
Tuesday, August 08, 2023
Monday, August 07, 2023
Thursday, August 03, 2023
Thursday, June 15, 2023
- Board Member at Bolt Biotherapeutics Acquires Company Stock Options Worth 25,000 Shares
- Director at Bolt Biotherapeutics Acquires Company Stock Options Worth 25,000 Shares
- Bolt Biotherapeutics Board Member Awarded $37K Worth of Stock Options
- Bolt Biotherapeutics Director Awarded $37K Worth of Stock Options
Monday, June 05, 2023
Tuesday, May 30, 2023
Friday, May 26, 2023
Friday, May 12, 2023
Wednesday, April 26, 2023
Thursday, March 30, 2023
- Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies
- Looking Into Bolt Biotherapeutics's Return On Capital Employed
- HC Wainwright & Co. Reiterates Buy on Bolt Bi...
- Bolt Biotherapeutics Announces Topline Data From BDC-1001 Phase 1 Dose-Escalation Trial In HER2-Expressing Tumors, Supporting Advancement To Phase 2 Clinical Studies